\ Scientific Presentations 2014
ASX Linkedin Twitter               

 

Scientific Presentations 2014

Presentation Title Conference Date
CALM study: A Phase II study of a novel oncolytic immunotherapeutic agent, Coxsackievirus A21, delivered intratumourally in patients with advanced malignant melanoma Society for Melanoma Research 2014 International Congress, Zurich  13-16 November 2014
Combination of a novel oncolytic immunotherapeutic agent, Coxsackievirus A21 and PD-1 or CTLA-4 blockade significantly reduces tumour growth in an immune competent mouse melanoma model The Society for Immunotherapy of Cancer Annual Meeting, Washington  6-9 November 2014
Combination of a novel oncolytic immunotherapeutic agent, Coxsackievirus A21 and PD-1 or CTLA-4 blockade significantly reduces tumour growth in an immune competent mouse melanoma model European Society for Medical Oncology, Madrid  26-30 September 2014
CALM Study: Secondary Endpoints of a Phase II study of a novel oncolytic immunotherapeutic agent, Coxsackievirus A21, delivered intratumorally in patients with advanced malignant melanoma European Society for Medical Oncology, Madrid  26-30 September 2014
CALM Study A Phase II study of an intratumourally delivered oncolytic immunotherapeutic agent (CVA21) in patients with stage IIIc and IV malignant melanoma American Society of Clinical Oncology, Chicago  30 May – 3 June 2014.
Major synergy between Coxsackievirus A21 (CAVATAKTM) and radiotherapy or chemotherapy in bladder cancer, due to up-regulation of viral receptors ICAM-1 & DAF The Eighth International Conference on Oncolytic Virus Therapeutics, Oxford, UK 9-13 April 2014.
Synergistic Activity of Coxsackievirus A21 (CVA21) and Docetaxel in Non-Small Cell Lung Cancer (NSCLC) The Eighth International Conference on Oncolytic Virus Therapeutics, Oxford, UK 9-13 April 2014.
Efficacy of CAVATAK against CD40L-stimulated CLL The Eighth International Conference on Oncolytic Virus Therapeutics, Oxford, UK 9-13 April 2014.
CAVATAK-mediated oncolytic immunotherapy in advanced melanoma patients American Association of Cancer Research Annual Meeting 5 – 9 April 2014

© Viralytics Limited 2018